Ayala Pharmaceuticals Inc (ADXS)

[bill_y]

tx_farmer wow.."We believe that we can use our Lm Technology with an number of antigens.".doc..universally engineered adjunct therapy. great article..confirms what we suspected to be true..

" and these immunotherapies just as easily have the potential to be added to the standard of care alongside frontline treatments, too.  There’s certainly a paradigm shift coming."

as for timeline "The Cures Act is important for Advaxis in a number of ways.."

multiple partnerships coming.." we have seen strong data suggesting how our lead product candidate, axalimogene filolisbac, will work well with Merck’s KEYTRUDA® and AstraZeneca’s duvalumab."

so much more in the article..finaly getting the word out